SWI QuickPicks Portfolio Up 29.2%
Los Angeles, Calif., November 23, 2016. Most analysts predicted the Dow to crash after election day. Instead it rose to a historical high on Wednesday. So did our SWI QuickPicks Portfolio; trading up another 1.2% adding 29.2% since inception. Even compared to a Dow historical high, we are doing just fine. As we have announced earlier, SWI has initiated three new stocks, which are now included in our SWI QuickPicks Portfolio.
Novocure (NVCR) is marketing its FDA approved Optune system and is testing new products in five (5) stage II/III clinical and nine (9) pre-clinical trials. NVCR is currently trading at $9.05 and has a BUY to STRONG BUY recommendation rating of 1.8 by four major analysts with a target price of $23.25.
Pfenex (PFNX) is a clinical-stage biotechnology company developing and commercializing high value
and difficult to manufacture proteins. The Company's initial focus is on biosimilar therapeutics and its
lead product is PF582, a biosimilar to Lucentis (ranibizumab). PFNX is currently trading at 10.05 and
has a a BUY recommendation rating of 1.8 by four major analysts with a target price of $20.00.
CytomX (CTMX) is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The company uses the platform to create proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. CTMX is currently trading at $12.03 and has a a BUY recommendation rating of 1.8 by four major analysts with a target price of $20.00.
As usual the SWI QuickPicks Portfolio is outperforming the S&P significantly. Have a happy Thanksgiving weekend.